An exterior view of the premises of Ab&B Bio-Tech. [Photo/WeChat account: weigg6666]
A special influenza vaccine independently developed by Ab&B Bio-Tech, located in the Taizhou Medical High-tech Zone in Taizhou city, East China's Jiangsu province, was recently approved to increase the vaccination population for toddlers aged 6 to 35 months.
The quadrivalent subunit influenza vaccine bypasses the previous age restriction that influenza subunit vaccines were only administered to those aged 3 years and above.
"Our vaccine does not require distinguishing between pediatric and adult dosage forms," said Chen Ze, chief scientist and deputy general manager of the company.
"People over six months old are vaccinated with the same dosage form and dose, simplifying the vaccination process and improving management efficiency," said Chen.
Chen added that at present, the widely used influenza vaccine in China was mainly the second-generation conventional split vaccine, while Ab&B Bio-Tech's vaccine belongs to the third-generation influenza vaccine.
The vaccine has undergone precise purification processes to remove any impurities, improving the purity of the vaccine and further reducing adverse reactions.